Shuttle Pharmaceuticals Holdings, Inc. Files S-1 Registration Statement

TL;DR

<b>Shuttle Pharmaceuticals Holdings, Inc. has filed an S-1 registration statement for an upcoming public offering.</b>

AI Summary

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) filed a IPO Registration (S-1) with the SEC on April 5, 2024. Shuttle Pharmaceuticals Holdings, Inc. filed an S-1 registration statement with the SEC on April 5, 2024. The company is incorporated in Delaware and its principal executive offices are located in Gaithersburg, MD. The filing indicates Shuttle Pharmaceuticals is a non-accelerated filer, smaller reporting company, and emerging growth company. The proposed sale of securities is to commence as soon as practicable after the effective date of the registration statement. Dorsey & Whitney LLP is listed as counsel for the registrant.

Why It Matters

For investors and stakeholders tracking Shuttle Pharmaceuticals Holdings, Inc., this filing contains several important signals. This S-1 filing is a prerequisite for Shuttle Pharmaceuticals to conduct an initial public offering (IPO) or a secondary offering, allowing it to raise capital for its operations and growth. As an emerging growth company and smaller reporting company, Shuttle Pharmaceuticals can utilize certain regulatory accommodations, potentially impacting its reporting requirements and compliance costs.

Risk Assessment

Risk Level: low — Shuttle Pharmaceuticals Holdings, Inc. shows low risk based on this filing. The filing is an S-1 registration statement, which is a standard procedural document for companies planning to go public, and does not contain specific financial performance data or operational updates that would indicate immediate risk.

Analyst Insight

Monitor future filings for details on the offering size, pricing, and use of proceeds to assess the company's capital-raising strategy and valuation.

Key Numbers

• S-1 — Form Type (Registration Statement)
• 2024-04-05 — Filing Date (Date filed with SEC)
• 333-278535 — SEC File Number (Registration Number)

Key Players & Entities

• Shuttle Pharmaceuticals Holdings, Inc. (company) — Registrant
• SEC (regulator) — U.S. Securities and Exchange Commission
• April 5, 2024 (date) — Filing Date
• Delaware (jurisdiction) — State of incorporation
• Gaithersburg, MD (location) — Principal executive offices
• Anatoly Dritschilo, M.D. (person) — Chief Executive Officer
• Dorsey & Whitney LLP (company) — Agent for service

FAQ

Industry Context

The filing is for a pharmaceutical company, operating within the biotechnology and pharmaceutical industry, which is characterized by significant research and development, regulatory hurdles, and capital requirements.

Regulatory Implications

The S-1 filing is a regulatory requirement under the Securities Act of 1933 for companies intending to offer securities to the public in the United States.

What Investors Should Do

1. Review the full S-1 filing for detailed information on the company's business, risk factors, and financial projections.
2. Track subsequent SEC filings (e.g., 424B filings) for details on the IPO pricing and share allocation.
3. Analyze the company's progress in its drug development pipeline and clinical trials once more information becomes available.

Key Dates

• 2024-04-05: S-1 Filing — Registration statement filed with the SEC.

Year-Over-Year Comparison

This is the initial S-1 filing, so there is no prior filing to compare against for 'vs last filing' data.

Key Financial Figures

• $4,500,000 — Subscription Rights to Purchase Up to $4,500,000 in Units Consisting of Up to Shares o
• $0.00001 — &rdquo;) of our common stock, par value $0.00001 per share (the &ldquo;Common Stock&rdqu
• $2.35 — e share of common stock, exercisable at $2.35 per share, and an interest in our wholl
• $2,250,000 — nt to which it is obligated to purchase $2,250,000 Units (the &ldquo;Committed Investment&
• $112,500 — e agreed to pay BSL a commitment fee of $112,500, payable in cash or shares, upon the ea
• $40,000 — of this offering, and we also paid BSL $40,000 to cover its due diligence fees in adva

Filing Documents

• forms-1.htm (S-1) — 819KB
• ex23-1.htm (EX-23.1) — 4KB
• ex23-2.htm (EX-23.2) — 3KB
• ex107.htm (EX-FILING FEES) — 42KB
• forms-1_001.jpg (GRAPHIC) — 8KB
• forms-1_002.jpg (GRAPHIC) — 26KB
• forms-1_003.jpg (GRAPHIC) — 18KB
• ex23-2_001.jpg (GRAPHIC) — 2KB
• 0001493152-24-013368.txt (&nbsp;) — 945KB

Risk Factors

Risk Factors 21 Special Note Regarding Forward-Looking Statements 2 7

Use of Proceeds

Use of Proceeds 28 Capitalization 29

Dilution

Dilution 30 Market Price of our Common Stock and Related Stockholder Matters 31 The Rights Offering 32 Material U.S. Federal Income Tax Consequences 40

Description of Capital Stock

Description of Capital Stock 50 Plan of Distribution 57 Experts 58 Legal Matters 58 ABOUT THIS PROSPECTUS The information in this prospectus is accurate only as of the date on the front cover of this prospectus, regardless of the time of delivery of this prospectus or any sale of any units hereunder. Our business, financial condition, results of operations and prospects may have changed since that date. You should also read and consider the information in the documents to which we have referred you under the caption &ldquo;Where You Can Find More Information&rdquo; in this prospectus. For investors outside the United States: We have not done anything that would permit a public offering of the securities or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities and the distribution of this prospectus outside of the United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus outside of the United States. You should rely only on the information contained in or incorporated by reference in this prospectus and in any free writing prospectus prepared by or on behalf of us. We have not authorized anyone to provide you with information different from, or in addition to, that contained in or incorporated by reference in this prospectus or any related free writing prospectus. This prospectus is an offer to sell only the securities offered hereby and only under circumstances and in jurisdictions where it is lawful to do so. The information contained in or incorporated by reference in this prospectus is current only as of its date. Our business, financial condition, results of operations and prospects

View Full Filing

View this S-1 filing on SEC EDGAR